您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
会议赞助商
403
2021 - 03 - 04
点击次数:
KCI Biotech (SUZHOU) Inc. (KCI) and Jiangsu KMQ biotech Inc. (KMQ) which is a wholly-owned subsidiary of KCI are preclinical Contract Research Organization (CRO) providing specialty preclinical pharmacology services in cardiovascular diseases, immune diseases, inflammatory diseases, metabolic diseases, urinary diseases, neuron diseases and oncology by using small (mice, rats, etc.) and large (non human primates, pigs, dogs, rabbits, guinea pig etc.) animal disease models. The core competency of KCI&KMQ stems from our pioneering work and expertise in developing and running specialized animal disease models to test drug candidates and medical devices for their pharmacological effects and biocompatible. We also conduct adjacency studies in PK/PD, preliminary toxicology, medical image, translational medicine and pathology.凯斯艾生物科技(苏州)有限公司(KCI)及其旗下的全资子公司江苏珂玛麒生物科技有限公司(KMQ)是一家为医药研发领域提供临床前药效及成药性评价技术服务的CRO公司。致力于建立小动物(小鼠,大鼠)、大动物(非人灵长类动物非人灵长类动物,猪,犬,兔,豚鼠等)综合性临床前药效及成药性评价平台。在心血管疾病、免疫性疾病、炎症性疾病、代谢性疾病、泌尿系统疾病,神经疾病和肿瘤疾病等领域提供专业的临床前药理药效学评价服务。KCI与KMQ的核心竞争力来源于我们的创新和专业开发以及运行专项的疾病动物模型,以测试候选药物和医疗器械的药理作用和生物相关性。我们还进行PK/PD,早期非GLP毒理学,医学影像学,转化医学和病理学的研究服务。 KCI locates in Suzhou industry park. We have 7200sq.ft. of SPF animal facility for about 7000 mice and 5000 rats studies at same time; 5400sq.ft. of experimental laboratories for pathology, cell biology, molecular biology,  formulation and other functional laboratories. KMQ, our large animal facility locates in Haimen (Linjiang), is about 50,000sq.ft. for guinea pigs, rabbits, dogs, pigs and NHP studies at same time; 22000sq.ft. of experimental laboratories for image facility including MRI, CT, X-ray, B-Ultrasound, operation rooms, cell biology, molecular biology,  formulation and other functional laboratories.凯斯艾位于苏州工业园区金鸡湖畔纳米城内,办公、实验面积1800㎡,其中大、小鼠SPF级屏障系统800㎡,功能性实验室600㎡,可同时开展7000只小鼠、5000只大鼠药理、药效学实验。同时旗下子公司珂玛麒拥有7600㎡的大动物实验基地(坐落在江苏海门临江生物医药园)。该实验基地拥有5000㎡的动物房,可同时开展豚鼠,兔,犬,猪以及实验非人灵长类动物的不同体内药效学实验,2000㎡的功能实验室设有MRI,CT,X-线,B-超实验室,动物手术室和其它功能实验室。 业务范围:基础生物医学研究      动物疾病模型应用病理学服务            转化
404
2021 - 03 - 01
点击次数:
恩斯克投资有限公司是日本精工株式会社(NSK Ltd.)的中国总部,全权负责中国大陆及香港的生产、技术、销售及营运。1960年代初,NSK开始进入中国进行轴承相关的技术交流。1992年在北京设立第一个事务所,1995年在江苏省昆山市建立第一家工厂,迄今,旗下在中国设立了生产、研发、销售公司及子公司30多家,遍及中国各地。恩斯克投资有限公司依托NSK集团总部的领导与支持,致力于向经济持续高速发展的中国引入先进的生产技术和管理经验,逐步确立并完善以“生产质量为基石,市场为导向,技术为核心”的三位一体化事业体制。同时,NSK还不断加快这一体制的本地化进程,旨在为中国的广大用户提供更直接、更完善的服务。   NSK(China) Investment Co., Ltd. is headquarter of NSK Ltd. in China, solely responsible for mainland China and Hong Kong production, technology, sales and operations.  In the beginning of the 1960s, NSK entered into China for the related bearing technical exchange programs. The first office was established in Beijing in 1992 and the first plant in Kunshan city, Jiangsu province was inaugurated in 1995. To date, NSK has set up over 30 production plants, R&D centers, sales offices and subsidiaries throughout China.  With leadership and support from NSK headquarter, NSK China is committed to a sustainable rapid economic development. Through introduction of advanced production technology and management experience, NSK China gradually establish and improve its integrated management system of “Production quality as cornerstone, Market-oriented and Technology as core”. Meanwhile, NSK continues to accelerate the localization process of the integrated system to provide a more direct and complete service for customers in China.
405
2021 - 01 - 29
点击次数:
威科集团是一家全球领先的专业信息服务提供商。来自世界各地法律、商业、税务、会计、金融、审计、风险管理、合规和医疗卫生等领域的专业人士依靠威科集团提供的信息工具及软件解决方案,来高效管理其业务,为其客户提供卓有成效的服务,助其在纷繁复杂的市场环境中取得成功。威科财务、风险和报告事业部 (FRR)  是属于威科集团的治理,风险与合规部门的一业务,是提供全球范围内综合监管合规和报告解决方案的领域的领导者,可帮助受监管的金融机构满足其外部合规机构及自身董事会提出的各项监管义务。威科财务、风险和报告事业部屡次获得其卓越和创新的独立认可的奖项。 《风险》杂志连续第二年授予威科财务、风险和报告事业部为年度最佳监管报告系统奖,而沃特世科技在其年度技术排名中将其评为最佳市场风险解决方案提供商。威科集团2018 年营业收入达43 亿欧元,在欧洲、北美、亚太和拉美地区运营,服务于全球客户。威科集团总部位于荷兰阿尔芬市市 阿姆斯特丹证券交易所代码:WKL)。 服务全球180 多个多家的客户,运营遍及全球40 多个国家, 在全球拥有18,600 名员工。关于威科风险和监管报告方案的更多讯息, 请访www.wolterskluwerfs.comGovernance, Risk & Compliance (GRC) is a division of Wolters Kluwer, which provides legal and banking professionals with solutions to ensure compliance with ever-changing regulatory and legal obligations, manage risk, increase efficiency, and produce better business outcomes. GRC offers a portfolio of technology-enabled expert services and solutions focused on legal entity compliance, legal operations management, banking product compliance, and banking regulatory compliance.Wolters Kluwer (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. Wolters Kluwer reported 2018 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 18,600 people worldwide.
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务